Table 3.

Unadjusted (A) and adjusted (B) Cox regression for graft survival. Shown are the various transformations of BALF biomarkers assessed. In the adjusted model, no covariates affected the model; covariates were recipient and donor gender, age, height, transplant type, diagnosis (restrictive/obstructive) and number of episodes of acute rejection. The adjusted effect of last measured CXCL9 and CXCL10 are shown here, even though they did not change the HR. The HR shown depicts the increased risk for incremental increase in biomarker measure. For the case of the last assessment of each biomarker, the HR reflects each 10 pg/mL increase. For the case of AUC, the HR reflects each 1000 pt increase in AUC

	Hazard ratio (95% CI)	p-Value
(A) Univariate biomarker transformation
CXCL9 last measure	1.06 (0.99–1.14)	0.07
CXCL9 AUC	1.07 (1.02–1.11)	<0.01
CXCL9 sum	1.22 (1–1.5)	0.05
CXCL9 mean	1.17 (1–1.38)	0.05
CXCL10 last measure	1.08 (1.03–1.13)	<0.01
CXCL10 AUC	1.03 (1.01–1.04)	<0.01
CXCL10 sum	1.13 (1.03–1.24)	0.01
CXCL10 AUC	1.08 (1.01–1.16)	0.02
IL-17 last measure	1.26 (1.05–1.52)	0.01
IL-17 AUC	0.96 (0.83–1.10)	0.55
IL1-RA last measure	1 (0.99–1.01)	0.81
IL1-RA AUC	1 (0.99–1.01)	0.75
MCP-1 last measure	1.02 (1.01–1.03)	<0.01
MCP-1 AUC	1 (0.99–1.01)	0.42
RANTES last measure	1.07 (0.92–1.24)	0.41
RANTES AUC	1.02 (1–1.04)	0.12
(B) Adjusted biomarker
CXCL9 AUC (adjusted for last measured CXCL9)	1.06 (1.02–1.11)	0.01
CXCL10 AUC (adjusted for last measured CXCL10)	1.02 (1.01–1.04)	0.01